A61K 31/505
Pyrimidines
Official title: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
A61K31/505 (Pyrimidines) appears on 19,924 US grants and 37,670 published applications in this corpus.
Search patents in A61K- Granted patents
- 19,924
- Published applications
- 37,670
- Assignees
- 8,894
- Inventors
- 59,646
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 47 | 0 |
| 1977 | 35 | 0 |
| 1978 | 18 | 0 |
| 1979 | 9 | 0 |
| 1980 | 17 | 0 |
| 1981 | 32 | 0 |
| 1982 | 19 | 0 |
| 1983 | 23 | 0 |
| 1984 | 23 | 0 |
| 1985 | 24 | 0 |
| 1986 | 26 | 0 |
| 1987 | 35 | 0 |
| 1988 | 46 | 0 |
| 1989 | 58 | 0 |
| 1990 | 48 | 0 |
| 1991 | 64 | 0 |
| 1992 | 67 | 0 |
| 1993 | 67 | 0 |
| 1994 | 62 | 0 |
| 1995 | 73 | 0 |
| 1996 | 97 | 0 |
| 1997 | 146 | 0 |
| 1998 | 151 | 0 |
| 1999 | 187 | 0 |
| 2000 | 203 | 0 |
| 2001 | 259 | 71 |
| 2002 | 259 | 378 |
| 2003 | 244 | 645 |
| 2004 | 202 | 712 |
| 2005 | 199 | 772 |
| 2006 | 261 | 821 |
| 2007 | 164 | 719 |
| 2008 | 191 | 783 |
| 2009 | 228 | 816 |
| 2010 | 345 | 966 |
| 2011 | 348 | 1023 |
| 2012 | 476 | 1088 |
| 2013 | 675 | 1466 |
| 2014 | 918 | 1911 |
| 2015 | 1156 | 2082 |
| 2016 | 1227 | 2074 |
| 2017 | 1406 | 2136 |
| 2018 | 1314 | 1927 |
| 2019 | 1353 | 2050 |
| 2020 | 1307 | 2039 |
| 2021 | 1147 | 2120 |
| 2022 | 1093 | 2179 |
| 2023 | 866 | 2193 |
| 2024 | 970 | 2407 |
| 2025 | 990 | 2370 |
| 2026 | 749 | 1922 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- A61K 31/519Ortho- or peri-condensed with heterocyclic rings10,365
- A61K 31/506Not condensed and containing further heterocyclic rings6,269
- A61K 31/517Ortho- or peri-condensed with carbocyclic ring systems2,412
- A61K 31/513Having oxo groups directly attached to the heterocyclic ring2,350
- A61K 31/527Spiro-condensed96
- A61K 31/529Forming part of bridged ring systems89
Recent patents
- Nanostructure or microstructure and method for producing same6 Oct 2026US 12,751,923 B2The University of Tokyo
- Crystalline forms of a BTK inhibitor6 Oct 2026US 12,751,949 B2Novartis AG
- Amorphous nilotinib microparticles and uses thereof6 Oct 2026US 12,751,950 B2Flex Pharma, LLC
- CDK inhibitors6 Oct 2026US 12,751,951 B2Genentech, Inc.
- MRGX receptor antagonists6 Oct 2026US 12,751,953 B2Katholieke Universiteit Leuven of KU Leuven Research & Development
- Tea compositions comprising paraxanthine and methods of production thereof8 Oct 2026US 2026/0305643 A1
- Methods of preventing post-traumatic osteoarthritis using metformin8 Oct 2026US 2026/0306428 A1
- Compositions, Kits, and Methods Comprising Bioidentical D BHB With Optional Vitamin B6 for Neurological Wellness, Mood Stability, and Medication Taper Support8 Oct 2026US 2026/0306430 A1Global Ketone Limited
- Nutritional compositions, supplements, and fortifiers8 Oct 2026US 2026/0306432 A1Societe des Produits Nestle S. A.
- Composition for removing and inhibiting senescent cells, and uses thereof8 Oct 2026US 2026/0306460 A1Lifeceutix Co., Ltd.
Most cited
By later US patents
- Wound dressing with conformable elastomeric wound contact layer1,263US 5,445,604 ASmith and Nephew Associated Companies Limited · 1995
- Anti-angiogenic compositions and methods of use968US 5,716,981 AAngiogenesis Technologies, Inc. · 1998
- Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation733US 9,101,621 B2Celgene Corporation · 2015
- Pharmaceutical compositions containing 5-methyltetrahydrofolic acid, 5-formyltetrahydrofolic acid and their pharmaceutically acceptable salts in controlled-release form active in the therapy of organic mental disturbances641US 5,059,595 ABioResearch Inc. · 1991
- Reversal of general anesthesia by administration of methylphenidate, amphetamine, modafinil, amantadine, and/or caffeine486US 10,299,720 B2The General Hospital Corporation · 2019